Sánchez-Borges Mario, Capriles-Hulett Arnaldo, Caballero-Fonseca Fernan
Centro Médico-Docente La Trinidad.
Clin Rev Allergy Immunol. 2003 Apr;24(2):125-36. doi: 10.1385/CRIAI:24:2:125.
Soon after the introduction of aspirin for the treatment of pain, fever, and inflammation more than a century ago, clinicians were challenged by the frequent observation of ASAtriggered allergic and pseudoallergic reactions occurring in the skin. This problem was further enhanced by the development of a number of other analgesic and antiinflammatory drugs that, having different chemical structures, cross-reacted with acetilsalycilic acid in many patients. This paper reviews the information presently available for the management of individuals who develop urticaria and angioedema when exposed to drugs that inhibit cyclooxygenase isoenzymes. The immune and nonimmunologic mechanisms leading to the pathogenesis of such reactions, their prevalence in selected groups of the population, clinical picture, and useful diagnostic approaches are described, and current guidelines used in our institutions for the clinical orientation of the patients, taking advantage of the recent introduction of various new and more selective NSAIDS that inhibit preferentially the COX-2 enzyme, are proposed.
一个多世纪前,阿司匹林开始用于治疗疼痛、发热和炎症后不久,临床医生就经常观察到阿司匹林引发的皮肤过敏和类过敏反应,这给他们带来了挑战。随着其他一些具有不同化学结构的镇痛和抗炎药物的研发,许多患者中这些药物与乙酰水杨酸发生交叉反应,使得这个问题更加严重。本文综述了目前关于接触抑制环氧化酶同工酶的药物时发生荨麻疹和血管性水肿的个体管理的可用信息。描述了导致此类反应发病机制的免疫和非免疫机制、在特定人群中的患病率、临床表现以及有用的诊断方法,并提出了我们机构目前用于指导患者临床治疗的指南,这些指南利用了最近引入的各种新型且更具选择性的非甾体抗炎药,这些药物优先抑制COX-2酶。